CBFB-MYH11 Inv(16) Detection Kit
£681.00
geneMAP™ CBFB-MYH11 Inv(16) Detection Kit for Leukemia are intended for the quantitative detection of CBFB-MYH11, fusion transcripts in bone marrow or peripheral blood samples. The results obtained are intended to be used as an aid to monitor efficacy of treatment in patients undergoing therapy, and for minimal residual disease (MRD) follow-up to monitor disease relapse.
CE-IVD
- Superior Analytical Sensitivity: Delivers a log4 reduction in detection sensitivity, enabling the identification of low levels of the CBFB-MYH11 fusion transcript.
- Fast and User-Friendly: Simplifies the testing process with one-step RT-qPCR technology, reducing time to results.
- Multiplex PCR: Allows for accurate relative quantitation by comparing fusion transcripts against ABL1 gene expression, enhancing diagnostic precision.
- Instrument Compatibility: Designed for use with FAM and VIC/HEX dual-color real-time PCR instruments, ensuring versatility across laboratory settings.
- CE-IVD Certification: Meets European standards for in vitro diagnostic medical devices, ensuring the kit’s quality and reliability for clinical use.
Leukemia Diagnosis and Monitoring: Specifically targets the CBFB-MYH11 Inv(16) fusion gene for patients suspected of or diagnosed with the Inv(16) subtype of acute myeloid leukemia (AML), playing a vital role in diagnosis, prognosis, and treatment monitoring strategies.
- Technology: Employs one-step RT-qPCR with multiplex PCR for the detection and relative quantitation of the CBFB-MYH11 fusion transcript.
- Sensitivity: Features superior analytical sensitivity (log4 reduction) for detecting low levels of the target gene.
- Compatibility: Compatible with FAM and VIC/HEX dual-color real-time PCR instruments.
- Certification: Carries the CE-IVD mark, indicating compliance with EU regulations for in vitro diagnostic use.
Why Choose Clent
We strive to enable our customers to focus on the results of their work, rather than the tools they use. Need to speak with a member of our team? Get in touch today.
